Dominari (NASDAQ:DOMH) Shares Down 0.8% – What’s Next?

Dominari Holdings Inc. (NASDAQ:DOMH)’s share price traded down 0.8% on Tuesday . The company traded as low as $2.54 and last traded at $2.56. Approximately 42,863 shares traded hands during trading, a decline of 23% from the average daily volume of 55,892 shares. The stock had previously closed at $2.58.

Wall Street Analysts Forecast Growth

DOMH has been the subject of a number of research analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Dominari in a research report on Monday, July 6th. Wall Street Zen raised Dominari from a “sell” rating to a “hold” rating in a report on Saturday, May 16th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Sell”.

Dominari Trading Up 0.4%

The stock has a market cap of $56.07 million, a P/E ratio of -0.62 and a beta of 0.87. The company’s 50 day moving average price is $2.96 and its two-hundred day moving average price is $3.18.

Dominari (NASDAQ:DOMH) last announced its earnings results on Wednesday, May 13th. The company reported ($2.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by ($1.94). Dominari had a negative net margin of 31.37% and a negative return on equity of 206.20%. The business had revenue of $35.81 million for the quarter, compared to the consensus estimate of $35.80 million.

Hedge Funds Weigh In On Dominari

A number of institutional investors have recently bought and sold shares of the stock. PFG Investments LLC lifted its position in Dominari by 36.3% during the first quarter. PFG Investments LLC now owns 14,475 shares of the company’s stock valued at $47,000 after purchasing an additional 3,855 shares in the last quarter. NewEdge Advisors LLC bought a new position in shares of Dominari in the fourth quarter worth about $50,000. Price T Rowe Associates Inc. MD bought a new position in shares of Dominari in the fourth quarter worth about $96,000. Oxford Asset Management LLP purchased a new position in shares of Dominari during the 4th quarter valued at about $120,000. Finally, Jane Street Group LLC bought a new position in shares of Dominari during the 2nd quarter valued at approximately $158,000. 42.48% of the stock is owned by institutional investors.

About Dominari

Dominari Holdings Inc, a biotechnology company, focuses on developing small-molecule anticancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The company is also developing an antiviral platform that inhibits replication of viruses, including influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2.